Merck and Moderna tout 5-year melanoma data

Still kicking after five years

Merck and Moderna rolled out a fresh batch of long-term data for intismeran autogene — the personalized mRNA cancer therapy formerly known as mRNA-4157 or V940 — paired with KEYTRUDA in patients with high-risk stage III/IV melanoma after surgery. The update comes from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, and the companies are basically saying: the combo hasn’t just held up, it’s still making a pretty persuasive case.

At a median follow-up of 60.3 months, the combo showed a 49% reduction in the risk of recurrence or death versus KEYTRUDA alone. It also cut the risk of distant metastasis or death by 59%. That’s the kind of number that can keep a pipeline story from drifting into the “nice science, not much stock-moving” bucket.

Why investors should care

This is still a Phase 2b story, so nobody’s hanging a victory banner from the ceiling yet. But in biotech, durability matters. A therapy that keeps showing a benefit years later is a lot more interesting than one that looks great in the first lap and then faceplants around the bend.

There was also an exploratory overall survival readout showing a favorable trend, with a hazard ratio of 0.471. That’s not a slam-dunk, practice-changing headline on its own, but it does add more fuel to the idea that personalized cancer vaccines could become a real commercial lane instead of just a conference-circuit crowd-pleaser.

The bigger picture

For Merck, this helps keep the KEYTRUDA franchise looking like the gift that keeps on giving. For Moderna, it’s another reminder that the company’s cancer ambitions are still very much part of the story, not just the vaccine hangover from the pandemic years.

Big picture: the oncology pipeline is a long game, and this update says Merck and Moderna are still in it — with data that actually gives investors something to chew on.